Q2 2026 saw 2% organic sales growth, margin expansion, and adjusted EBITDA of €398m, with strong performance in Asia and ongoing merger preparations with Axalta. FY 2026 guidance remains unchanged, targeting adjusted EBITDA of at least €1.47bn and stable leverage.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.